This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. By the numbers   Q3 revenue: $1.21 billion 22% increase year over year   Net income: $283.8 million Compared with $134.6 million in Q3 2024 Dexcom’s leadership said Thursday that the company has fixed problems with its flagship glucose monitor after reports of quality issues with its latest G7 sensor. The diabetes technology company has recently faced a lawsui ...

Abbott Laboratories (NYSE:ABT) is one of the 12 Set-It-and-Forget-It Stocks to Buy Now. Amid a positive second quarter and a top executive sale, the company gains an expansion opportunity from Medtronic. Abbott Gains Diabetes Tech Expansion Opportunity Following Earnings Beat and Insider Sale Abbott Laboratories (NYSE:ABT) reported a 6.9% increase in sales for the second quarter of 2025. The earnings report, announced on July 17, 2025, also highlighted an Adjusted EPS of $1.26, which beat the consensus ...